Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
Dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease; Program update expected in the first half of 2025New England Journal of Medicine publication of Phase 1 study of RP-A501 to treat patients with Danon diseaseLong-term data from the Phase 1 trial of RP-A501 for Danon disease presented at AHA on safety and meaningful efficacyEnrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM; Initial data expected in the first half of 2025Regulatory reviews ongoing for KRESLADI (severe LAD-I) and RP-L102 (Fanconi Anemia)Cash, cash equivalents and investments of approximately $372.3M; expected operational runway into the third quarter of 2026 CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and yea
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness Wire
- Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lowered by analysts at Bank of America Corporation from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
RCKT
Earnings
- 11/6/25 - Beat
RCKT
Sec Filings
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- RCKT's page on the SEC website